Overview
LBRX market data
Price History
LBRX price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$1.00 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.59 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $13.36 – $49.14 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $1.3B · P/B 1.87.
Company News
BMO Capital Maintains Outperform on LB Pharmaceuticals, Raises Price Target to $54Benzinga · Aug 12, 2026, 12:05 PM
8-K filing — LB PHARMACEUTICALS INC (LBRX)SEC EDGAR · Aug 11, 2026, 12:05 PM
LB Pharmaceuticals Q2 EPS $(1.71) Misses $(0.80) EstimateBenzinga · Aug 11, 2026, 12:05 PM
HC Wainwright & Co. Reiterates Buy on LB Pharmaceuticals, Maintains $45 Price TargetBenzinga · Aug 3, 2026, 10:33 AM
LB Pharmaceuticals shares are trading higher after the company announced a $150 million private placement.Benzinga · Jul 29, 2026, 2:45 PM
LB Pharmaceuticals Commences ~$150M Offering Of Common Shares, Pre-Funded WarrantsBenzinga · Jul 29, 2026, 12:01 PM
LB Pharmaceuticals shares are trading higher after the company announced accelerated timing for topline results from the Phase 3 NOVA-2 trial of LB-102 in Schizophrenia.Benzinga · Jul 22, 2026, 5:55 PM
LB Pharmaceuticals Announces Accelerated Timing of Topline Results from the Phase 3 NOVA-2 Trial of LB-102 in SchizophreniaGlobenewswire Inc · Jul 22, 2026, 12:15 PM
LB Pharma Now Expects To Report Topline Results From Pivotal Phase 3 NOVA-2 Clinical Trial Of LB-102 In Patients With Schizophrenia In H1 Of 2027 And To Schedule Pre-NDA Meeting With FDA In H2 Of 2027Benzinga · Jul 22, 2026, 12:02 PM
BMO Capital Initiates Coverage On LB Pharmaceuticals with Outperform Rating, Announces Price Target of $46Benzinga · Jul 21, 2026, 9:34 AM